Icon reaffirms FY2026 guidance after Q1 revenue rises 0.9%
Icon reported Q1 2026 revenue of $2,034.0 million, a 0.9% increase from the prior year, with an adjusted EBITDA margin of 15.6%. Net business wins reached $2.88 billion, driven by gross bookings of $3,263 million. The company reaffirmed its full-year 2026 guidance for revenue of $7.85 billion to $8.15 billion and adjusted diluted EPS of $10.00 to $11.00.
*this image is generated using AI for illustrative purposes only.
Icon reported financial results for the first quarter ended March 31, 2026, with revenue reaching $2,034.0 million, a 0.9% increase compared to the prior year period. The clinical research organization posted an adjusted EBITDA of $317.7 million, representing 15.6% of revenue, while GAAP net income stood at $104.8 million. The company maintained strong commercial momentum, evidenced by net business wins of $2,880 million and a net book-to-bill ratio of 1.42, which drove a 4.0% increase in closing backlog to $22.7 billion.
CEO Mr. Barry Balf attributed the performance to robust gross award activity and low cancellations, supported by partnerships added in the second half of 2025 and two new partnerships during the quarter. Despite the impact of business mix on financial performance, management expressed confidence in executing its strategic plan throughout 2026. Net debt was $2.6 billion as of March 31, 2026, with a net debt to adjusted EBITDA ratio of 1.8x.
First Quarter 2026 Financial Highlights
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $2,034.0 million | $2,015.3 million | 0.9% |
| Adjusted EBITDA | $317.7 million | $398.1 million | (20.2)% |
| GAAP Net Income | $104.8 million | $160.8 million | (34.9)% |
| Adjusted Net Income | $192.9 million | $264.8 million | (27.2)% |
| Diluted EPS (GAAP) | $1.36 | $1.99 | (31.7)% |
| Adjusted Diluted EPS | $2.50 | $3.27 | (23.5)% |
Operational Performance
Gross bookings for the quarter totaled $3,263 million with cancellations of $383 million, determined under a new policy effective October 1, 2025. Free cash flow was $136.2 million, driven by $167.0 million in cash generated from operating activities and $30.8 million in capital expenditure. The company made $7.4 million in Term Loan B payments during the quarter. Cash and cash equivalents increased to $765.2 million from $647.3 million at the end of December 31, 2025.
Icon reaffirmed its full-year 2026 financial guidance, expecting revenue in the range of $7,850 million to $8,150 million and adjusted diluted earnings per share between $10.00 and $11.00. The revenue outlook compares to an analyst estimate of $8.022 billion, while the EPS guidance compares to a $10.55 estimate. The guidance excludes items such as amortization, stock-based compensation, foreign currency gains and losses, restructuring, and transaction-related costs.
How will the change in cancellation policy effective October 1, 2025, impact the comparability of future backlog and net business win metrics?
What specific strategies will management employ to improve Adjusted EBITDA margins throughout the remainder of 2026 given the significant decline in the first quarter?
With net debt at $2.6 billion, does the company plan to accelerate debt repayments or prioritize capital expenditures to support the growing backlog?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
